MedTrace Logo

The Effects of Repetitive Transcranial Magnetic Stimulation in Healthy Human Subjects

NCT00658307 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-05-02

No results posted yet for this study

Summary

It has been suggested that the therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) are mediated through changes in cortical inhibition (CI). However, in healthy subjects the effects of rTMS on CI have been inconsistent. The aim of this study is to explore different rTMS - stimulus conditions neurophysiological and molecular mechanisms in the human motor cortex. Fifty-six healthy subjects will be randomized into three different treatment groups and receive 1 active or sham rTMS session (6000 rTMS pulses) at 90% of their motor threshold (MT). Cortical inhibition will be indexed pre and post treatment using short-interval intracortical inhibition (SICI), cortical silent period (CSP) and long-interval cortical inhibition (LICI).

Based on previous studies we hypothesize that:

* Hypothesis 1: rTMS will result in a greater CI (i.e., prolonged CSP, increased LICI but not SICI) compared to sham rTMS.
* Hypothesis 2: 20 Hz rTMS will result in a significantly greater CI compared to 1 Hz rTMS.
* Hypothesis 3: There will be distinctive transcription profiles associated with increases in CI from rTMS that can be detected with whole-genome microarray analysis of peripheral leukocytes.

Conditions

  • Healthy

Interventions

DEVICE

repetitive transcranial magnetic stimulation (rTMS)

1 Hz The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)

DEVICE

repetitive transcranial magnetic stimulation (rTMS)

20Hz The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)

DEVICE

sham repetitive transcranial magnetic stimulation (rTMS)

The rTMS device is the "MagPro X100 Series" (produced by Magventure A/S, Farum, Denmark)

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Jeff Daskalakis, MD, PhD · Centre for Addiction and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658307 on ClinicalTrials.gov